학술논문
Dose reduction is a feasible strategy in patients with plaque psoriasis who achieve sustained response with secukinumab: a retrospective, multicenter cohort study in daily practice setting.
Document Type
Article
Author
Daudén, Esteban; Escario, Elena; Martos‐Cabrera, Luisa; Armesto, Susana; Herrera‐Acosta, Enrique; Vidal, David; Vilarrasa, Eva; Rivera, Raquel; de la Cueva, Pablo; Martorell, Antonio; Ballesca, Ferran; Belinchón, Isabel; Carretero, Gregorio; Rodríguez, Lourdes; Romero‐Maté, Alberto; Pujol‐Montcusí, J.; Salgado, Laura; Sahuquillo‐Torralba, Antonio; Coto‐Segura, Pablo; Baniandrés, Ofelia
Source
Subject
*COHORT analysis
*PSORIASIS
*BIOTHERAPY
*
*
Language
ISSN
0011-9059
Abstract
Background: Biological therapy dose modification is a common practice in the long‐term treatment of plaque psoriasis. Objective: The objective of the study was to determine prevalence, characteristics of patients, effectiveness, treatment survival of secukinumab dose reduction (SEC‐DR) strategy and assess its safety and cost implications. Methods: A retrospective, observational, multicenter cohort study was conducted in patients with plaque psoriasis treated with secukinumab and up to 2 years of follow‐up. Results: In 63/347 patients with an initial standard dose regimen, SEC‐DR was tried at any moment in 18.2% of them after sustained response. In 51 patients, the interval between administrations was increased while in 12 patients, monthly dose was reduced to 150 mg. Successful SEC‐DR was achieved in 77.8% of the patients, with sustained PASI response to the end of the study. Survival of secukinumab treatment and safety profile were not compromised by DR. The use of DR saved 33% of the cost, including failures in which standard treatment was resumed. Limitations: The proper of the study designed and the arbitrary definition of "DR success." Conclusion: Off‐label SEC‐DR strategy was used in patients with sustained response to standard dose regimen; this strategy showed long‐term efficacy without compromising treatment survival or worsening the safety profile while also being cost saving. [ABSTRACT FROM AUTHOR]